{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Summary statistics, such as mean, median, counts and proportion, will be used to summarize the patients. Potential association between variables will be measured using Pearson correlation coefficients, chi-square tests, one- or two-sample t-tests or logistic regression analyses as appropriate. Non-parametric tests such as Spearman correlation coefficients, Fisher's exact tests and Wilcoxon rank sum test may be substituted if necessary. 95% percent confidence intervals will be constructed and selected results will be illustrated using figures and plots.","groups":[{"description":"Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15, then on day 1 beginning cycle 5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.\n\nBiopsy Procedure: Undergo tumor biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nCabozantinib S-malate: Given PO\n\nComputed Tomography: Undergo CT scan\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"OG000","title":"Arm A (Cabozantinib S-malate, Nivolumab)"},{"description":"Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time of disease progression. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan, MRI, and blood sample collection throughout the study and undergo biopsy at screening and optionally at follow up.\n\nBiopsy Procedure: Undergo tumor biopsy\n\nBiospecimen Collection: Undergo blood sample collection\n\nComputed Tomography: Undergo CT scan\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"OG001","title":"Arm B (Nivolumab)"}],"paramType":"NUMBER","populationDescription":"Pre-specified to only evaluate participants in Arm A and B; as Arm C was an exploratory cohort.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage"}